Myelofibrosis: Looking Beyond Survival and Splenic Response (Implications & Adapting during Pandemic)

At the recent 18th Annual Scientific Meeting of the Malaysian Society of Haematology (MSH), Professor Dr Claire Harrison, clinical director at Guy’s and St Thomas’ NHS Foundation Trust, UK, presented an overview of myelofibrosis (MF) management considerations from a patient-centric perspective and the therapeutic role of ruxolitinib (Jakavi®, Novartis). The satellite symposium was organized by Novartis in collaboration with the MSH.